Anti‐monocyte chemoattractant protein‐1 gene therapy inhibits restenotic changes (neointimal hyperplasia) after balloon injury in rats and monkeys
- 5 September 2002
- journal article
- Published by Wiley in The FASEB Journal
- Vol. 16 (13) , 1-17
- https://doi.org/10.1096/fj.02-0094fje
Abstract
Prevention of restenosis after coronary intervention is a major clinical challenge, which highlights the need of new therapeutic options. Vascular injury may involve inflammatory responses that accelerate the recruitment and activation of monocytes through the activation of chemotactic factors, including monocyte chemoattractant protein‐1 (MCP‐1). However, there is no definitive evidence supporting the role of MCP‐1 in restenosis. We recently devised a new strategy for anti‐MCP‐1 gene therapy by transfecting an N‐terminal deletion mutant of the MCP‐1 gene into skeletal muscles. We demonstrate here that this strategy suppressed monocyte infiltration/activation in the injured site and markedly inhibited restenotic changes (neointimal hyperplasia) after balloon injury of the carotid artery in rats and monkeys. This strategy also suppressed the local production of MCP‐1 and inflammatory cytokines. Therefore, monocyte infiltration and activation mediated by MCP‐1 are essential in the development of restenotic changes after balloon injury. This strategy may be a useful form of gene therapy against human restenosis.Keywords
This publication has 22 references indexed in Scilit:
- Chemokines and diseaseNature Immunology, 2001
- AtherosclerosisNature, 2000
- Atherosclerosis — An Inflammatory DiseaseNew England Journal of Medicine, 1999
- Frontiers in Interventional CardiologyCirculation, 1998
- Absence of Monocyte Chemoattractant Protein-1 Reduces Atherosclerosis in Low Density Lipoprotein Receptor–Deficient MiceMolecular Cell, 1998
- Interleukin-8 (IL-8) and monocyte chemotactic and activating factor (MCAF/MCP-1), chemokines essentially involved in inflammatory and immune reactionsCytokine & Growth Factor Reviews, 1998
- Restenosis Revisited — New Targets, New TherapiesNew England Journal of Medicine, 1997
- Detection of monocyte chemoattractant protein-1 in human atherosclerotic lesions by an anti-monocyte chemoattractant protein-1 monoclonal antibodyHuman Pathology, 1993
- JE mRNA accumulates rapidly in aortic injury and in platelet-derived growth factor-stimulated vascular smooth muscle cells.Circulation Research, 1992
- Expression of monocyte chemoattractant protein 1 in macrophage-rich areas of human and rabbit atherosclerotic lesions.Proceedings of the National Academy of Sciences, 1991